What is it about?
This is a correction notice for our previously published article by Morroni et al. in Antibiotics, which studied in the laboratory the activity of aztreonam combined with old and new beta-lactamase inhibitors against Gram-negative bacteria producing both metallo-beta-lactamases (MBLs) and extended-spectrum beta-lactamases (ESBLs). These bacteria are resistant to almost all beta-lactam antibiotics, and combining aztreonam, which is not destroyed by MBLs, with an inhibitor that blocks the other enzymes is one of the few possible treatment strategies. The correction updates details of the original publication without changing its scientific conclusions.
Featured Image
Photo by Testalize.me on Unsplash
Why is it important?
Keeping the scientific record accurate is essential. The original study supports aztreonam-based combinations as a possible option for complicated infections caused by MBL- and ESBL-co-producing bacteria, an urgent clinical problem with very limited therapeutic choices.
Perspectives
Corrections are part of good scientific practice. The original work, carried out with colleagues in Ancona and other Italian centres, addresses one of the most difficult resistance patterns we face in the clinic, and I am glad its record is now complete and accurate.
Professor Stefano Di Bella
Universita degli Studi di Trieste
Read the Original
This page is a summary of: Correction: Morroni et al. Antimicrobial Activity of Aztreonam in Combination with Old and New β-Lactamase Inhibitors against MBL and ESBL Co-Producing Gram-Negative Clinical Isolates: Possible Options for the Treatment of Complicated Infections. Antib..., Antibiotics, March 2022, MDPI AG,
DOI: 10.3390/antibiotics11040464.
You can read the full text:
Contributors
The following have contributed to this page







